Acknowledgement

This activity is provided by Talem Health and RME Collaborative.

 
This online program is recorded content from the live session at Oncology Congress Fall 2025 and is co-supported by independent medical education grants from AbbVie, Inc.; AstraZeneca Pharmaceuticals; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Novartis Pharmaceuticals Corporation; and Regeneron Pharmaceuticals, Inc. This activity is supported by an independent medical education grant from AbbVie, Inc.

Credit Available

• Physicians — maximum of 1.0 AMA PRA Category 1 Credit™
• Nurses — 1.0 Contact Hour (0.5 contact hour of pharmacotherapy credit)
• Pharmacists — 1.0 Contact Hour (0.1 CEU)

All other healthcare professionals completing this course will be issued a statement of participation.

Target Audience

This activity is designed specifically for community oncologists, advanced practice providers, and other members of the healthcare team who serve patients from rural and underserved communities.

Program Overview

Surgical cytoreduction, often combined with systemic platinum-based chemotherapy, remains the standard of care for ovarian cancer. However, patients face poor long-term survival and treatment-related tolerability, and the disease is often not detected and managed until advanced stages, adding to the complexity. Recent advances have expanded therapeutic options, including targeted therapies, maintenance strategies, and novel combination approaches. However, access to these agents and integration into individualized care plans remain key considerations, particularly in community and rural oncology settings. This on-demand CME/CE activity will review the latest efficacy and safety data of emerging therapies for advanced ovarian cancer, including strategies for identifying and managing side effects. Expert faculty will also discuss treatment personalization and collaborative approaches to overcome the unique disparities in rural and underserved communities.

This enduring activity is a recorded session from Oncology Congress that took place on October 25, 2025.

Learning Objectives

Upon completion of this activity, participants should be better able to:

• Evaluate the safety and efficacy of current and emerging therapies for advanced ovarian cancer
• Develop personalized management plans for patients with advanced ovarian cancer considering new evidence, evolving treatment algorithms, and patient preferences
• Use collaborative approaches to improve access to ovarian cancer care and enhance patient engagement in rural and underserved communities

Faculty

Ursula A. Matulonis, MD
Professor of Medicine
Harvard Medical School
Chief, Division of Gynecologic Oncology
Brock-Wilson Family Chair
Dana-Farber Cancer Institute
Boston, MA

Chris Prakash, MD 
Director, Quality Services - Texas Oncology
Chair, Medical Oncology Quality - Texas Oncology
Past President, Texas Society of Clinical Oncology
Medical Director, Texas Oncology - Paris 
Paris, TX

Joint Accreditation Statement

In support of improving patient care, Talem Health is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Credit Designation

Physician Continuing Medical Education
Talem Health designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Continuing Nursing Education
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour. Designated for 0.5 contact hour of pharmacotherapy credit for Advanced Practice Registered Nurses.

Continuing Pharmacy Education
Talem Health designates this continuing education activity for 1.0 contact hour (0.1 CEU) of the Accreditation Council for Pharmacy Education.
(Universal Activity Number – JA4008332-0000-26-028-H01-P)
Type of Activity: Application

Disclosure of Conflicts of Interest

Talem Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of a CE activity, including faculty, planners, reviewers, or others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All identified conflicts of interest are thoroughly vetted and mitigated according to Talem Health policy. Talem Health is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

All relevant financial relationships have been mitigated.

The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity:

Faculty

Ursula A. Matulonis, MD, has disclosed the following relevant financial relationships: advisory board member for AbbVie, Inc., Daiichi Sankyo, Inc., Day One Biopharmaceuticals, Inc., Eisai, Inc., GSK, ImmunoGen (now AbbVie, Inc.), NextCure, Inc., Novartis Pharmaceuticals Corporation, Ovarian Cancer Research Alliance, ProfoundBio, Inc. (now Genmab), Tango Therapeutics, Inc., and Whitehawk Therapeutics, Inc.; data safety monitoring board member for AstraZeneca Pharmaceuticals, Daiichi Sankyo, Inc., MacroGenics, Inc., Mural Oncology, and Servier Symphogen.

Chris Prakash, MD, has disclosed the following relevant financial relationships: speakers’ bureau/honoraria from Myriad Genetics, Inc.

Planners, Managers, and Reviewer 

The Talem Health planners, managers, and reviewer have nothing to disclose.

Instructions for Participation and Credit

This activity is offered at no cost to participants. To receive CME credit, participants must:

1. Read the CME/CE information, including learning objectives and disclosure statements.
2. Complete the pre-test.
3. View the online activity.
4. Complete the post-test and evaluation form.

A post-test score of 67% or higher is required to obtain credit. Your certificate will be made available for immediate download.

Course Viewing Requirements

Supported Browsers:
Desktop/laptop: Newest and last prior version of Google Chrome, Firefox, Safari, and Microsoft Edge
Mobile devices: Newest and last prior version of Safari and Google Chrome

Supported Phones & Tablets:
All devices

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

RME Collaborative, a division of Talem Health, LLC. All Rights Reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Talem Health, LLC is prohibited.

Media

Internet activity

Fee Information

There is no fee for this educational activity.

Contact Information

For questions about this activity, please contact RME Collaborative (a division of Talem Health) at 800-913-9370 or cme@cmeruralhealth.com.